Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1CNS 1Breast 1

Conditions

Glioblastoma 5Neoplasms 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Gliosarcoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Docetaxel 8Radiotherapy 6Filgrastim 4Bevacizumab 4Paclitaxel 3Nivolumab 3Magnetic Resonance Spectroscopy 3Erlotinib Hydrochloride 3Cisplatin 3Cetuximab 3Carboplatin 3Capecitabine 3regorafenib 2pembrolizumab 2Radiotherapy, Intensity-Modulated 2Gemcitabine 2Cyclophosphamide 2Chemotherapy, Adjuvant 2Biopsy 2Acupuncture Therapy 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tanespimycin 1spartalizumab 1sargramostim 1oncogene protein E7, Human papillomavirus type 16 1oblimersen 1fluoromisonidazole 1fludarabine phosphate 1etoposide phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × depatuxizumab mafodotin × CNS × Clear all
NCT02365662 2018-03-30

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

AbbVie

Phase 1 Terminated
46 enrolled
BreastCNSGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡